Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
about
Inflammation, oxidative stress and renin angiotensin system in atherosclerosisAnti-inflammatory therapies for cardiovascular diseaseAssociation of traditional risk factors with coronary artery disease in nonagenarians: the primary role of hypertensionCytosolic phospholipase A(2)α protects against ischemia/reperfusion injury in the heart.Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.Anti-inflammatory therapeutics for the treatment of atherosclerosis.Risk stratification in cardiovascular disease primary prevention - scoring systems, novel markers, and imaging techniques.New lipid-lowering drugs: an update.Regression of atherosclerosis.Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012).The role of inflammatory biomarkers in developing targeted cardiovascular therapies: lessons from the cardiovascular inflammation reduction trials.Immune-mediated mechanisms of atherosclerosis and implications for the clinic.Matrix metalloproteinase-2 negatively regulates cardiac secreted phospholipase A2 to modulate inflammation and fever.Inflammation and atherosclerosis: disease modulating therapies.Snake Venom PLA2, a Promising Target for Broad-Spectrum Antivenom Drug Development.Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction.
P2860
Q26795756-0AFB55F8-FB4B-4FC4-BFE6-7E88A791E5CDQ34137872-AC578BF6-92AA-4B05-8FFA-68B47FBC72BDQ34564055-EE6EE13B-B834-4AC0-AE85-39B356C7BF3BQ35205874-9F5C0F8A-0C11-4DFF-BE5F-D80AF8D966BBQ37303915-6B9A947F-87A9-4B3C-8F80-3AF2705D094EQ37626768-3D51EBAC-B54B-41E6-882C-DD1677A7C0B4Q37973386-AE0B5D73-691B-424B-95BC-B14BC4458F9FQ37984782-4A43F76A-8DB9-40C7-B65E-C0587D38A1E5Q38019423-5F146097-0743-40FE-8FA4-8D0E67E83FA1Q38136273-D2E6BAB1-528D-472E-A592-FB3A801E3898Q38593722-4E838CE6-10DA-42B1-AC36-D37E100AF21AQ38851472-0ECF0F40-790F-4921-962A-D39D040B4DA5Q38893588-91374886-177A-4391-AD9E-BF30EDE193D9Q39360950-BE37381B-719B-400E-8D7D-3935ED1A0DA4Q48274979-BD628053-2902-4D6C-AA4C-CF024E143BCBQ52609376-A01D553C-F9A6-4C9A-94D2-F1CBE8702098
P2860
Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Randomized trial of an inhibit ...... s with coronary heart disease.
@ast
Randomized trial of an inhibit ...... s with coronary heart disease.
@en
Randomized trial of an inhibit ...... s with coronary heart disease.
@nl
type
label
Randomized trial of an inhibit ...... s with coronary heart disease.
@ast
Randomized trial of an inhibit ...... s with coronary heart disease.
@en
Randomized trial of an inhibit ...... s with coronary heart disease.
@nl
prefLabel
Randomized trial of an inhibit ...... s with coronary heart disease.
@ast
Randomized trial of an inhibit ...... s with coronary heart disease.
@en
Randomized trial of an inhibit ...... s with coronary heart disease.
@nl
P2093
P2860
P356
P1476
Randomized trial of an inhibit ...... s with coronary heart disease.
@en
P2093
Colin Hislop
Michael Elliott
PLASMA II Investigators
Robert S Rosenson
Yuri Stasiv
P2860
P304
P356
10.1093/EURHEARTJ/EHQ374
P577
2010-11-16T00:00:00Z